Okay, let's tackle this question about prolactinoma in pregnancy. The question is asking which statement is false. First, I need to recall what I know about prolactinomas and their management during pregnancy.

Prolactinomas are benign tumors of the pituitary gland that secrete prolactin. During pregnancy, estrogen levels rise, which can stimulate the growth of these tumors. So, I remember that they tend to enlarge in pregnancy. That might be one of the facts here. Also, treatment with dopamine agonists like bromocriptine is typically paused during pregnancy because of potential risks to the fetus. Instead, monitoring is done, and sometimes surgery is considered if the tumor is causing symptoms. However, during pregnancy, the main concern is the tumor's size and the risk of complications like headaches or visual field defects.

Wait, but the question is an EXCEPT question. So the false statement would be something that's not true. Let me think about the options. Let's say the options include statements about tumor size increase, drug discontinuation, management during pregnancy, and possible complications.

If one of the options says that dopamine agonists are continued throughout pregnancy, that would be incorrect because they are usually discontinued. Another incorrect option might be that the tumor shrinks during pregnancy, which is false because they usually enlarge. Also, maybe a statement about the risk of hyperprolactinemia causing infertility in pregnancy would be incorrect because in pregnancy, the body's normal prolactin levels rise, so the hyperprolactinemia might not affect fertility in the same way. Wait, but in pregnancy, the woman is already pregnant, so infertility isn't an issue here. That might not be the right angle.

Another point: Prolactinomas can lead to galactorrhea, but in pregnancy, galactorrhea is common due to hormonal changes, so that might not be a distinguishing factor. But if an option says that galactorrhea is a common symptom in pregnant women with prolactinoma, that's true. So maybe that's not the exception.

Putting it all together, the false statement might be something like "Dopamine agonists are the first-line treatment during pregnancy," which is incorrect because they are usually stopped, and management is more about monitoring. Alternatively, if an option states that the tumor decreases in size during pregnancy, that's false because they typically increase.

I need to make sure the correct answer is the one that's false. Let me check the possible options again. The correct answer here is the one that's not true. So if the options include statements about tumor size increase, drug discontinuation, potential need for surgery, and the correct answer is the one that says dopamine agonists are used during pregnancy, that's the false one. So the EXCEPT answer would be the statement that dopamine agonists are continued in pregnancy.

**Core Concept**
Prolactinomas are estrogen-sensitive pituitary adenomas that typically enlarge during pregnancy due to increased estrogen levels. Dopamine agonists (e.g., bromocriptine) are contraindicated in pregnancy due to teratogenic risks, and management focuses on monitoring tumor size and addressing complications like visual field deficits.

**Why the Correct Answer is Right**
Dopamine agonists inhibit prolactin secretion by activating D2 receptors on lactotrophs. However, they are avoided in

✓ Correct Answer: C. Macroadenoma > 1 cm is associated with bad prognosis